San Diego, California–(Newsfile Corp. – May 3, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) (“Tryp”) a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced today a master service agreement with Fluence to provide design and training for the psychotherapeutic portion of Tryp’s clinical trial activities.


Previous articleChampignon Brands Changes Name to Braxia Scientific to Reflect the Integration of Ketamine and Psychedelic Clinics and its Research and Development Priorities
Next articlePsyched Wellness Signs Supply Agreement for Amanita Muscaria